Drugs / PP1M
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03345342 Background | Nov 2017 → May 2020 | schizophrenia | Janssen Research & Development, LLC | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PP1M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03345342 ↗ |
| Route | Intramuscular | “Participants will receive intramuscular injection of PP1M 50 to 150 mg eq.” NCT03345342 ↗ |